Sugi Predict

Sugi Predict / Compounds / SCHEMBL145350

SCHEMBL145350

SCHEMBL145350

O=C(O)c1cc2c(Br)cccc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 1/20 0.58
▸ KDM4E B2RXH2 3/20 0.57
▸ HSD17B10 Q99714 3/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ HPGD P15428 2/20 0.57
▸ GRIN1 Q05586 2/20 0.57
▸ HRH4 Q9H3N8 1/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ GRIN2D O15399 1/20 0.57
▸ GRIN3B O60391 1/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ GLA P06280 1/20 0.57
▸ GAA P10253 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ AHR P35869 1/20 0.57
▸ CHRNA7 P36544 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ GRIN2A Q12879 1/20 0.57
▸ GRIN2B Q13224 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30097060 1.00 FLT3 (0.58) FLT3KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL30295665 0.84 FLT3 (0.57) FLT3KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL924331 0.84 FLT3 (0.57) FLT3KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL19625090 0.80 FLT3 (0.53) FLT3KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL2205092 0.80 HRH4 (0.56) FLT3KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL31414534 0.80 HRH4 (0.56) FLT3KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL1076712 0.80 HRH4 (0.56) FLT3KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL2806087 0.80 KDM4E (0.59) KDM4EHSD17B10ALDH1A1HPGDGRIN1
SCHEMBL2762336 0.80 KDM4E (0.59) FLT3KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL3417091 0.80 FLT3 (0.60) FLT3KDM4EHSD17B10ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2948454-B1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) 2017-05-31 — — EP claimed
CN-106220551-A The synthetic method of 4 bromine 2 oxyindoles 叶芳 2016-12-14 — — CN claimed
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 — — US disclosed
US-20250120961-A1 P53 MODULATORS NESTED THERAPEUTICS INC (US) 2025-04-17 — — US disclosed
EP-4219460-B1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA INC (US) 2025-02-26 — — EP disclosed
US-20250011324-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA, INC., 2025-01-09 — — US disclosed
US-12152026-B2 Transglutaminase 2 (TG2) inhibitors SITARI PHARMA, INC. (US) 2024-11-26 — — US disclosed
CN-115297861-B Compounds and uses thereof 福宏治疗公司 2024-07-12 — — CN disclosed
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2024-02-08 — — US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-20030199689-A1 New indole derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-10-23 — — US disclosed
WO-2003044014-A1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-05-30 — — WO disclosed
CN-1396833-A Integrin expression inhibitors EISAI CO LTD (JP) 2003-02-12 — — CN disclosed
EP-1258252-A1 INTEGRIN EXPRESSION INHIBITORS Eisai Co., Ltd. (JP) 2002-11-20 — — EP disclosed
EP-1000063-B1 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI SYNTHELABO (FR) 2002-10-23 — — EP disclosed
CN-1294579-A Sulfonamide-containing indole compounds EISAI CO LTD (JP) 2001-05-09 — — CN disclosed
CN-1265591-A Coumpound ZENECA LTD (GB) 2000-09-06 — — CN disclosed
EP-1000063-A1 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO 4,5-$i(b)]-INDOLE-1-ACETAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI-SYNTHELABO (FR) 2000-05-17 — — EP disclosed
WO-1999006406-A1 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]-INDOLE-1-ACETAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI-SYNTHELABO (FR) 1999-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12152026-B2 Transglutaminase 2 (TG2) inhibitors TGM2, TGM3, TGM1 FLT3 4708/4885KDM4E 2034/4885HSD17B10 2195/4885
US-20250011324-A1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS TGM2, TGM3, TGM1 FLT3 4708/4885KDM4E 2034/4885HSD17B10 2195/4885
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB FLT3 3450/4885KDM4E 1848/4885HSD17B10 1370/4885
US-20250120961-A1 P53 MODULATORS TP53, TP53BP1, MDM2 FLT3 3349/4885KDM4E 4412/4885HSD17B10 2074/4885
US-11807644-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS FLT3 2571/4885KDM4E 3311/4885HSD17B10 3076/4885
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS FLT3 2571/4885KDM4E 3311/4885HSD17B10 3076/4885
US-20030199689-A1 New indole derivatives as factor Xa inhibitors F5, F12, F2 FLT3 693/4885KDM4E 1206/4885HSD17B10 2805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.